Semaglutide Explained: Ozempic vs Wegovy vs Rybelsus, the Wegovy Pill and Label Doses

Semaglutide is the active ingredient in Ozempic, Wegovy, Rybelsus and the newer Ozempic and Wegovy pills. All come from Novo Nordisk, but they differ in form, dose, approved use and daily routine. This guide sets out what the US labels say as of September 2026, what the main trials found, and where generic semaglutide stands.

What is semaglutide and how does it work?

Semaglutide is a man-made version of GLP-1, a gut hormone that helps control blood sugar and appetite. It is a GLP-1 receptor agonist peptide: it switches on the same receptors as your own GLP-1 but lasts far longer, with a half-life of about one week, so it can be taken once a week by injection or once a day as a tablet.

The labels describe it as 94% similar in sequence to human GLP-1 and heavily bound to albumin, a blood protein that shields it from breakdown. It works in three ways: it prompts insulin release and lowers glucagon when blood sugar is high, it acts on brain areas that regulate appetite and food intake, and it slightly delays stomach emptying after meals.

Ozempic vs Wegovy vs Rybelsus: what is the difference?

All of these products contain semaglutide. Ozempic and the diabetes tablets are approved for type 2 diabetes, while Wegovy, as a weekly injection or a daily pill, is approved for weight management and heart-risk reduction. Top doses differ too: 2 mg for Ozempic, 2.4 mg for Wegovy, 7.2 mg for Wegovy HD and 25 mg for the Wegovy pill.

• Wegovy HD is the 7.2 mg pen. The label allows it for adults who have tolerated 2.4 mg for at least 4 weeks and need more weight reduction; its safety is not established in children or in MASH.
• The Ozempic pill is a reformulated tablet. Novo Nordisk calls it a US name change from Rybelsus, which will continue to be marketed outside the US. The label says the two are not substitutable milligram for milligram.
• The Wegovy label says not to combine it with other semaglutide products or with any other GLP-1 receptor agonist.

What are the semaglutide dose steps on the US label?

Every semaglutide product starts low and steps up about once a month to reduce stomach side effects. Wegovy injections climb from 0.25 mg to a 1.7 mg or 2.4 mg maintenance dose over 16 weeks, and the Wegovy pill climbs from 1.5 mg to 25 mg over 90 days. Your prescriber decides each step.

More label rules:

• If a step is not tolerated, the Wegovy label says to consider delaying escalation (by 4 weeks for the injection).
• If the 25 mg pill is not tolerated, it says to consider the 1.7 mg weekly injection instead.
• For chronic kidney disease, the Ozempic maintenance dose is 1 mg weekly.
• Missed-dose rules differ by product; see our missed-dose guide.

These are label facts, not instructions. Check any change with your prescriber or pharmacist.

What else is semaglutide approved for?

Beyond blood sugar and weight, semaglutide has three outcome-based US approvals. Wegovy lowers the risk of heart attack, stroke and cardiovascular death in adults with heart disease and excess weight (March 2024). Ozempic lowers kidney-failure risk in type 2 diabetes with kidney disease (January 2025). Wegovy also treats the liver disease MASH (August 2025).

• Heart (SELECT). In 17,604 adults aged 45 or older with heart disease and overweight or obesity but no diabetes, Wegovy lowered the risk of a first major cardiovascular event by 20% (hazard ratio 0.80) over a median of about 42 months. The Wegovy pill shares this indication.
• Kidneys (FLOW). In 3,533 adults with type 2 diabetes and chronic kidney disease, Ozempic 1 mg lowered the risk of major kidney decline, kidney failure or cardiovascular death by 24% (hazard ratio 0.76) over a median of 41 months.
• Liver (MASH). Wegovy injection is approved for noncirrhotic MASH with moderate to advanced fibrosis (stages F2 to F3). It is an accelerated approval based on liver biopsies at 72 weeks, so continued approval may depend on a confirmatory trial.

How much weight do people lose on semaglutide?

In the main trials, adults without diabetes lost an average of about 14% to 19% of body weight over 64 to 72 weeks, depending on form and dose, compared with 2% to 4% on placebo. People with type 2 diabetes lost less. These are averages: some people lose much more, and some much less.

In STEP 1, 86% of people on semaglutide lost at least 5% of their weight and about half lost at least 15%. All four trials included diet and activity counseling, and they enrolled different people, so they are not a head-to-head test of pill versus injection. For semaglutide compared with tirzepatide, see our tirzepatide guide.

Wegovy pill vs injection: how do they compare?

The Wegovy pill and injection contain the same drug and share the adult weight-management and heart-risk approvals. The injection is taken once a week at any time, with or without food. The pill is taken every morning under strict fasting rules. Average weight loss in their pivotal trials was similar, about 14% to 15%.

The US label's pill rules:

1. Take one tablet each morning on an empty stomach.
2. Swallow it whole with plain water only, up to 4 ounces (half a cup).
3. Wait at least 30 minutes before eating, drinking anything else or taking other oral medicines.
4. Take no more than one tablet a day. If you miss one, skip it and take the next dose the following day.

The rules protect absorption. The label estimates that only about 1% to 2% of a tablet's semaglutide is absorbed (89% for the injection), and absorption was higher with less water and a longer wait. Blood levels also varied more: 27 to 186 nmol/L for 90% of people on 25 mg tablets, versus 51 to 110 nmol/L on the 2.4 mg injection. Rybelsus and the Ozempic pill follow the same rules.

Two more differences: the pill is approved only for adults, and in a study with the tablet, levothyroxine exposure rose 33%, so the label advises monitoring oral medicines that need it.

What are the common side effects of semaglutide?

Stomach and bowel symptoms are the most common side effects. In the Wegovy 2.4 mg trials, 44% of adults reported nausea, 30% diarrhea, 24% vomiting and 24% constipation, compared with 16%, 16%, 6% and 11% on placebo. The label says these reactions were reported most often during dose escalation.

• Other Wegovy 2.4 mg rates: abdominal pain 20% (placebo 10%), headache 14% (10%), fatigue 11% (5%) and hair loss 3% (1%).
• Wegovy HD (7.2 mg): nausea 39%, vomiting 22% and hair loss 6%, versus 35%, 16% and 3% on 2.4 mg in the same trials. Dysesthesia (tingling, burning or sensitive skin) affected 22%, versus 6% on 2.4 mg.
• Ozempic: nausea in 15.8% on 0.5 mg and 20.3% on 1 mg, versus 6.1% on placebo.
• Wegovy pill: similar types and frequency to the injection, per the label.

Our side-effects timeline shows how symptoms usually change week by week.

The boxed warning

Every semaglutide label carries a boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it does in humans. The labels say not to use it if you or a family member has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 2. Report a lump in the neck, trouble swallowing, shortness of breath or lasting hoarseness.

When to call your doctor

The Wegovy Medication Guide lists these warning signs:

• Severe stomach pain that will not go away, with or without vomiting (possible pancreatitis).
• Upper stomach pain, fever, yellow skin or eyes, or clay-colored stools (possible gallbladder problems).
• Nausea, vomiting or diarrhea that does not go away, which can cause dehydration and kidney problems.
• Swelling of the face, lips, tongue or throat, trouble breathing or swallowing, fainting or a very rapid heartbeat. Get emergency help for a possible serious allergic reaction.

Tell every care team that you take semaglutide before any surgery or sedation.

How long does semaglutide stay in your body?

Semaglutide has a half-life of about one week, so levels build up over 4 to 5 weeks on a dose and fall slowly after the last one. The Wegovy label says it stays in the circulation for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection or 25 mg tablet.

The daily tablets have the same one-week half-life. The long tail is also why the Wegovy label advises stopping at least 2 months before a planned pregnancy. Our guide to how long GLP-1 medications stay in your body compares the class.

Is there a generic semaglutide in 2026?

No generic semaglutide is on sale in the US as of September 2026, and compounded semaglutide is not an FDA-approved generic. Outside the US, generics arrived in 2026 in some countries: they launched in India after the compound patent expired on March 20, 2026, and Health Canada approved its first generic on April 28, 2026.

• United States. Drugs@FDA lists one generic of Ozempic, from Apotex, as tentatively approved in April 2026, with its marketing status shown as none, so it is not on sale. The main compound patent in the FDA Orange Book runs to December 5, 2031.
• Canada. Health Canada says it was the first G7 country to approve a generic semaglutide and had seven more applications under review in May 2026.
• India. Novo Nordisk told investors that competitors launched generics there after the patent expired.

For how compounded products differ, see our guide to compounded GLP-1s.

What to do next

A few practical steps help you use semaglutide as labeled and get more out of prescriber visits.

• Confirm your exact product. Each brand and form has its own strengths and rules, and tablets are not interchangeable milligram for milligram.
• Keep a dated log. Note when each dose step started and how you felt afterward. A tracker such as GLP Calendar can log injections, pill times and side-effect check-ins and build a PDF for appointments.
• Plan pill mornings. Build in the 30-minute wait and ask your pharmacist how to time other morning medicines, especially thyroid medicine.
• Know the red flags. Severe stomach pain that will not go away, dehydration or an allergic reaction needs prompt care.
• Ask before changing anything. Switching forms, moving to 7.2 mg, surgery and pregnancy plans are prescriber decisions.